Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

Bariatric surgery reduces the progression to decompensated cirrhosis and the risk for major adverse liver outcomes, such as ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...

Rye Single Barrels are uncut, unfiltered, malt-forward whiskeys that were inspired by the distillery’s first experimental ...

Metabolic surgery significantly lowered risk for major adverse liver outcomes vs. nonsurgical management among patients with ...

While Solís dancing to Lamar’s “Not Like Us” might come as a surprise to many, the rapper’s November album GNX has hints of ...

Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic ...

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in ...

Shares of Madrigal Pharmaceuticals ( MDGL 16.35%) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...